World Ovarian Cancer Day 2023

Following cervical and uterine cancer, ovarian cancer (OC) ranks third in gynecologic cancers for frequency but has the highest rate of death. A woman’s risk of getting ovarian cancer during her lifetime is about 1 in 78, with a mortality rate of around 1 in 108. OC often remains non-diagnosed until it spreads throughout the pelvis and abdomen, making treatment difficult.

For World Ovarian Cancer Day 2023, we'd like to highlight some of our most impactful research and review articles on OC in the last few years, which have extensively contributed to the field.

We'd like to congratulate our authors on this achievement, which cements Journal of Ovarian Research as a top destination for OC content.

For all articles on ovarian cancer, please see here.

For more information on WOCD from the World Ovarian Cancer Coalition including how to get involved, please see here.

Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection
_{Sima Chaudhari, Satyajit Dey Pereira, Meshach Asare-Warehene, Ritam Naha, Shama Prasada Kabekkodu, Benjamin K. Tsang & Kapaettu Satyamoorthy}
_{Review | Published: 25 February 2021}

COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
_{Antonio Macciò, Sara Oppi & Clelia Madeddu}
_{Review | Published: 08 February 2021}

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
_{Zhen Yuan, Ying Zhang, Dongyan Cao, Keng Shen, Qingshui Li, Guonan Zhang, Xiaohua Wu, Manhua Cui, Ying Yue, Wenjun Cheng, Li Wang, Pengpeng Qu, Guangshi Tao, Jianqing Hou, Lixin Sun, Yuanguang Meng, Guiling Li, Changzhong Li, Huirong Shi & Yaqing Chen}
_{Research | Published: 11 January 2021}

Ovarian endometrioid carcinoma and clear cell carcinoma: A 21-year retrospective study
_{Ling Zhou, Liqing Yao, Lin Dai, Honglan Zhu, Xue Ye, Shang Wang, Hongyan Cheng, Ruiqiong Ma, Huiping Liu, Heng Cui & Xiaohong Chang}
_{Research | Published: 04 May 2021}

Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
_{Juan Zou, Yukun Li, Nianchun Liao, Jue Liu, Qunfeng Zhang, Min Luo, Jiao Xiao, Yanhua Chen, Mengjie Wang, Kexin Chen, Juan Zeng & Zhongcheng Mo}
_{Research | Published: 28 February 2022}

Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis
_{Jue Zhu, Lifeng Yan & Qiming Wang}
_{Research | Published: 28 August 2021}

Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses
_{Kiarash Tanha, Azadeh Mottaghi, Marzieh Nojomi, Marzieh Moradi, Rezvan Rajabzadeh, Samaneh Lotfi & Leila Janani}
_{Review | Published: 11 November 2021}

The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials
_{Xin-Ru Li, Yi Zhu, Guo-Nan Zhang, Jian-Ming Huang & Li-Xia Pei}
_{Research | Published: 09 March 2021}

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study
_{Dengfeng Wang, Guonan Zhang, Chunrong Peng, Yu Shi & Xunwei Shi}
_{Research | Published: 27 March 2021}

The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
_{Jing Ni, Xianzhong Cheng, Qian Zhao, Zhiqin Dai, Xia Xu, Wenwen Guo, Hongyuan Gu, Rui Zhou, Yan Wang & Xiaoxiang Chen}
_{Research | Published: 17 May 2021}

Calculating the dose of cisplatin that is actually utilized in hyperthermic intraperitoneal chemotherapy among ovarian cancer patients
_{Wu-yun Wang, Miao-fang Wu, Dong-bing Wu, Li-juan Wang, Hui Li, Zhong-qiu Lin & Jing Li}
_{Research | Published: 08 January 2021}

Challenges and opportunities for ovarian cancer management in the epidemic of Covid-19: lessons learned from Wuhan, China
_{Zhilan Chen, Chun Zhang, Jiu Yin, Xin Xin, Hemei Li, Yapei Wang, Benjamin K. Tsang & Qinghua Zhang}
_{Review | Published: 08 February 2021}

Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review
_{Shona Nag, Shyam Aggarwal, Amit Rauthan & Narayanankutty Warrier}
_{Review | Published: 28 July 2022}

Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status
_{Yongsong Wu, Shilin Xu, Shanshan Cheng, Jiani Yang & Yu Wang}
_{Review | Published: 07 January 2023}

Exosome-mediated transfer of CD44 from high-metastatic ovarian cancer cells promotes migration and invasion of low-metastatic ovarian cancer cells
_{Xiameng Shen, Conghui Wang, Huihui Zhu, Yaping Wang, Xinyu Wang, Xiaodong Cheng, Wanzhong Ge & Weiguo Lu}
_{Research | Published: 24 February 2021}

MiR-200b is upregulated in plasma-derived exosomes and functions as an oncogene by promoting macrophage M2 polarization in ovarian cancer
_{Jun Xiong, Xiaoju He, Yuanyuan Xu, Wei Zhang & Fen Fu}
_{Research | Published: 02 June 2021}

Plasma-derived exosomal miR-4732-5p is a promising noninvasive diagnostic biomarker for epithelial ovarian cancer
_{Jingjing Liu, Jigeun Yoo, Jung Yoon Ho, Yuyeon Jung, Sanha Lee, Soo Young Hur & Youn Jin Choi}
_{Research | Published: 28 April 2021}

Integrated clinical characteristics and omics analysis identifies a ferroptosis and iron-metabolism-related lncRNA signature for predicting prognosis and therapeutic responses in ovarian cancer
_{Songwei Feng, Han Yin, Ke Zhang, Mei Shan, Xuan Ji, Shanhui Luo & Yang Shen}
_{Research | Published: 20 January 2022}

Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis
_{Sifan Sun & Hailiang Fang}
_{Research | Published: 16 November 2021}

COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
_{Antonio Macciò, Sara Oppi & Clelia Madeddu}
_{Review | Published: 08 February 2021}

MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A
_{Jin Wang & Lingxia Liu}
_{Research | Published: 19 November 2021}

RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis
_{Shengtan Wang, Zaihong Li, Genhai Zhu, Lan Hong, Chunyan Hu, Kang Wang, Kaiying Cui & Chunbo Hao}
_{Research | Published: 13 November 2021}

Propofol suppresses cell viability, cell cycle progression and motility and induces cell apoptosis of ovarian cancer cells through suppressing MEK/ERK signaling via targeting circVPS13C/miR-145 axis
_{Huan Lu, Guanlin Zheng, Xiang Gao, Chanjuan Chen, Min Zhou & Longxin Zhang}
_{Research | Published: 09 February 2021}

MiR-585-3p suppresses tumor proliferation and migration by directly targeting CAPN9 in high grade serous ovarian cancer
_{Xiaoyuan Lu, Guilin Li, Sicong Liu, Haihong Wang & Buze Chen}
_{Research | Published: 08 July 2021}

Establishment and validation of an RNA binding protein-associated prognostic model for ovarian cancer
_{Chaofan He, Fuxin Huang, Kejia Zhang, Jun Wei, Ke Hu & Meng Liang}
_{Research | Published: 07 February 2021}

Exosomes secreted by chemoresistant ovarian cancer cells promote angiogenesis
_{Zhang Li, Wang Yan-qing, Yang Xiao, Liu Shi-yi, Yuan Meng-qin, Xian Shu, Yang Dong-yong, Zheng Ya-jing & Cheng Yan-xiang}
_{Research | Published: 07 January 2021}

MicroRNAs as the critical regulators of Cisplatin resistance in ovarian cancer cells
_{Meysam Moghbeli}
_{Review | Published: 30 September 2021}

Early clearance of serum HE4 and CA125 in predicting platinum sensitivity and prognosis in epithelial ovarian cancer
_{Yan Rong & Li Li}
_{Research | Published: 04 January 2021}

Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients
_{Jianfeng Zheng, Jialu Guo, Linling Zhu, Ying Zhou & Jinyi Tong}
_{Research | Published: 24 September 2021}

COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?
_{Antonio Macciò, Sara Oppi & Clelia Madeddu}
_{Review | Published: 08 February 2021
Altmetric Attention}

Comprehensive analyses of glycolysis-related lncRNAs for ovarian cancer patients
_{Jianfeng Zheng, Jialu Guo, Linling Zhu, Ying Zhou & Jinyi Tong}
_{Research | Published: 24 September 2021
Altmetric Attention}

Pretreatment with LCK inhibitors chemosensitizes cisplatin‐resistant endometrioid ovarian tumors
_{Katie K. Crean-Tate, Chad Braley, Goutam Dey, Emily Esakov, Caner Saygin, Alexandria Trestan, Daniel J. Silver, Soumya M. Turaga, Elizabeth V. Connor, Robert DeBernardo, Chad M. Michener, Peter G. Rose, Justin Lathia & Ofer Reizes}
_{Research | Published: 22 April 2021
Altmetric Attention}

Comparison of the survival outcomes of laparoscopy versus laparotomy in treatment of early-stage ovarian cancer: a systematic review and meta-analysis
_{Qingduo Kong, Hongyi Wei, Jing Zhang, Yilin Li & Yongjun Wang}
_{Research | Published: 16 March 2021
Altmetric Attention}

Predicting chemoresponsiveness in epithelial ovarian cancer patients using circulating small extracellular vesicle-derived plasma gelsolin
_{Emma Gerber, Meshach Asare-Werehene, Arkadiy Reunov, Dylan Burger, Tien Le, Euridice Carmona, Anne-Marie Mes-Masson & Benjamin K. Tsang}
_{Research | Published: 16 January 2023
Altmetric Attention}

A bioinformatics analysis: ZFHX4 is associated with metastasis and poor survival in ovarian cancer
_{Shuai Zong, Ping-ping Xu, Yin-hai Xu & Yi Guo}
_{Research | Published: 01 August 2022
Altmetric Attention}

Using genetically encoded fluorescent biosensors to interrogate ovarian cancer metabolism
_{Shree Bose, Haipei Yao, Qiang Huang, Regina Whitaker, Christopher D. Kontos, Rebecca A. Previs & Xiling Shen}
_{Research | Published: 20 October 2022
Altmetric Attention}

World Ovarian Cancer Day 2023

Annual Journal Metrics

Journal of Ovarian Research

Contact us